Drug Search Results
More Filters [+]

NUC-7738

Alternative Names: nuc-7738, nuc7738, nuc 7738
Latest Update: 2024-08-29
Latest Update Note: News Article

Product Description

NUC-7738 is a ProTide transformation of 3'-deoxyadenosine (3'-dA), also known as cordycepin. 3’-dA has demonstrated potent anti-cancer activity in non-clinical studies, but has not been successfully developed as a anti-cancer agent due to its rapid breakdown by adenosine deaminase (ADA). It is a nucleoside analog. (Sourced from: https://www.nucana.com/nuc7738.html)

Mechanisms of Action: RNA Synthetase Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Nucana
Company Location: EDINBURGH X0 EH12 9DT
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NUC-7738

Countries in Clinic: United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NuTide:701

P2

Recruiting

Lymphoma

2024-06-01

Recent News Events